Citadel Advisors
PRLD icon

Citadel Advisors’s Prelude Therapeutics PRLD Stock Holding History

Citadel Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Sell
22,554
-101,824
-82% -$443K ﹤0.01% 12533
2026
Q1 		$425K Buy
+124,378
New +$326K ﹤0.01% 9691
2025
Q3 		– Sell
-33,625
Closed -$27.2K – 13807
2025
Q2 		$27.2K Buy
33,625
+33,591
+98,797% +$29.1K ﹤0.01% 12021
2025
Q1 		$26 Sell
34
-10,263
-100% -$9.57K ﹤0.01% 14355
2024
Q4 		$13.1K Sell
10,297
-4,928
-32% -$6.54K ﹤0.01% 13460
2024
Q3 		$31.5K Sell
15,225
-16,163
-51% -$74.9K ﹤0.01% 12387
2024
Q2 		$120K Buy
31,388
+1,593
+5% +$6.48K ﹤0.01% 10658
2024
Q1 		$141K Sell
29,795
-65,535
-69% -$255K ﹤0.01% 10858
2023
Q4 		$407K Sell
95,330
-204,771
-68% -$623K ﹤0.01% 8532
2023
Q3 		$927K Buy
300,101
+263,232
+714% +$988K ﹤0.01% 6723
2023
Q2 		$166K Buy
+36,869
New +$220K ﹤0.01% 10175
2023
Q1 		– Sell
-18,232
Closed -$110K – 15318
2022
Q4 		$110K Buy
18,232
+2,498
+16% +$16K ﹤0.01% 11084
2022
Q3 		$104K Sell
15,734
-93,889
-86% -$633K ﹤0.01% 11056
2022
Q2 		$572K Buy
109,623
+58,725
+115% +$299K ﹤0.01% 8338
2022
Q1 		$352K Sell
50,898
-87,602
-63% -$801K ﹤0.01% 10217
2021
Q4 		$1.73M Buy
138,500
+124,005
+856% +$2.02M ﹤0.01% 6594
2021
Q3 		$453K Buy
+14,495
New +$469K ﹤0.01% 10117
2021
Q2 		– Sell
-19,496
Closed -$845K – 14251
2021
Q1 		$845K Buy
+19,496
New +$1.29M ﹤0.01% 8520
2020
Q4 		– Sell
-110,915
Closed -$3.34M – 11393
2020
Q3 		$3.34M Buy
+110,915
New +$3.13M ﹤0.01% 3804

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Citadel Advisors's PRLD Position: Q2 2026 in Review

Citadel Advisors reduced its Prelude Therapeutics (PRLD) stake by 82% in Q2 2026, selling an estimated $443K and leaving 22,554 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #12533.

Citadel Advisors first reported a position in PRLD in Q3 2020 and has held it in 19 quarters since. The position peaked at $3.34M in Q3 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Citadel Advisors held 22,554 shares of Prelude Therapeutics worth $120K as of Q2 2026.
  • Citadel Advisors sold 101,824 Prelude Therapeutics shares in Q2 2026, an estimated $443K.
  • Prelude Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12533 holding.
  • Citadel Advisors first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Prelude Therapeutics position peaked at $3.34M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.